Inferra AIResearch Tools

Inferra AI / Company / IRON

Disc Medicine, Inc.

IRON · Health Care

Last earnings Jul 30, 2026

AI analysis

Q2 2025 · reported Aug 7, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The Company expects that its existing cash, cash equivalents and marketable securities as of June 30, 2026 of $ 717.7 million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements.

treasury securities $ 441,097 $ 57 $ ( 1,119 ) $ 440,035 Corporate debt securities 89,493 ( 89 ) 89,404 U.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Disc Medicine, Inc. Q2 2025 results

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

The Company expects that its existing cash, cash equivalents and marketable securities as of June 30, 2026 of $ 717.7 million will enable the Company to fund its planned operating expense and capital expenditure requirements for at least twelve months from the date of issuance of these condensed consolidated financial statements.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

treasury securities $ 441,097 $ 57 $ ( 1,119 ) $ 440,035 Corporate debt securities 89,493 ( 89 ) 89,404 U.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

treasury securities $ 484,670 $ 859 $ $ 485,529 Corporate debt securities 132,913 44 ( 16 ) 132,941 U.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

government agency, and corporate debt securities are subject to minimal credit risk.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

treasury securities 440,035 Corporate debt securities 89,404 U.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

treasury securities 485,529 Corporate debt securities 132,941 U.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

Strategy & priorities

(NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a recap of recent program and corporate developments.

SEC original ↗Disc Medicine, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions.

SEC original ↗Disc Medicine, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Our forward-looking statements include, but are not limited to, statements regarding our or our management team s expectations, hopes, beliefs, intentions or strategies regarding the future.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

Our programs are focused on the development of therapeutics for patients with hematologic diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to approved or marketable products.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

(together with its subsidiaries, the Company ) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

Risks & headwinds

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.

SEC original ↗Disc Medicine, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 28 Item 1A.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

These forward-looking statements are based on information available to us at the time of this Quarterly Report on Form 10-Q and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

Our existing and any future indebtedness could adversely affect our ability to operate our business.

SEC original ↗Disc Medicine, Inc. — 10-Q Quarterly report10-QJul 30, 2026

Documents

Earnings deck slides

0 decks with slide view

Disc Medicine, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Disc Medicine, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

32 documents

Earnings releases

12 documents

Presentations

2 documents

Transcripts

0 documents

No transcripts for Disc Medicine, Inc. are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Disc Medicine, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.